Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: BioMarin
Man Max 99 years
BioMarin Pharmaceutical Inc
Update Il y a 4 ans
A study to test if BMN 053 is safe and effective in people who suffer from Duchenne muscular dystrophy
To assess the efficacy of BMN 053 at recommended dosing regimen after 48 weeks treatment in ambulant subjects with Duchenne muscular dystrophy.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
BioMarin Pharmaceutical Inc
Update Il y a 4 ans
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Phenoptin in Subjects with Phenylketonuria Who Have Elevated Phenylalanine Levels
The primary objective is to evaluate the efficacy of Phenoptin in reducing blood Phe levels in subjects with phenylketonuria.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
BioMarin Pharmaceutical Inc
Update Il y a 4 ans
A Phase 2, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Phenoptin in Subjects with Hyperphenylalaninemia Due to Primary BH4 Deficiency
The primary objective of the study is: • To evaluate the ability of Phenoptin treatment to control blood phenylalanine levels in subjects with HPA due to primary BH4 deficiency.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
BioMarin Pharmaceutical Inc
Update Il y a 4 ans
A Phase 4 Multi-center, Multi-national, Open-label, Randomized, Two Dose Level Study of Naglazyme (galsulfase) in Infants with Maroteaux-Lamy Syndrome (MPS VI)
The primary objective of the study is to evaluate the efficacy of two dose levels of Naglazyme in preventing the progression of skeletal dysplasia in infants under the age of one year who have MPS VI ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
BioMarin Pharmaceutical Inc
Update Il y a 4 ans
An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients with CLN2 Disease
The primary objectives of this study include the following: •to evaluate the long-term safety of BMN 190 administration at 300 mg qow in patients with CLN2 •to assess change in motor and language su...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
BioMarin Pharmaceutical Inc
Update Il y a 4 ans
A Phase 3b, Multicenter, Open-Label Extension Study of Phenoptin in Subjects with Phenylketonuria Who Participated in Protocols PKU-004 or PKU-006
The objective of this study is to evaluate the safety of long-term treatment with Phenoptin in subjects with phenylketonuria (PKU) who participated in Phase 3 clinical studies with Phenoptin.
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Aker BioMarine Antarctic AS
Update Il y a 4 ans
A Single Centre, Open-Label, Randomised Multi-Dose Study to Assess Changes in the Brain Metabolism of Juvenile ADHD Patients After Thirteen Weeks of Daily Intake of 4 g Superba Krill Oil or 4 g omega-3 Enriched Fish Oil
To evaluate changes in the brain metabolism of juvenile ADHD patients after thirteen weeks of daily doses of 4 g Superba krill oil or 4 g omega-3 enriched fish oil
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
BioMarin Pharmaceutical Inc
Update Il y a 4 ans
Estudio de fase 3 controlado con placebo para evaluar la seguridad y eficacia del fosfato de amifampridina Phase 3 placebo controlled study to evaluate safety and efficacy of Amifampridine phosphate
Eficacia: Comparar la eficacia del fosfato de amifampridina frente al placebo en la fuerza muscular de los pacientes con LEMS al final de un periodo de interrupción de 14 días Seguridad Evaluar la se...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman
Between 18 years
and 99 years
BioMarin
Update Il y a 4 ans
ABRAZO : Essai de phase 2, évaluant l’efficacité et la tolérance d’un inhibiteur de PARP, le BMN 673, chez des patientes ayant un cancer du sein localement avancé ou métastatique avec une mutation des gènes BRCA1 ou BRCA2. [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité et la tolérance du BMN 673, un inhibiteur de PARP, chez des patientes ayant un cancer du sein localement avancé ou métastatique avec une mutation du ...
Country
France
organs
Sein
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
BioMarin Pharmaceutical Inc
Update Il y a 4 ans
A Phase 2, Multicenter, Open-Label, Exploratory Biomarker Study of Talazoparib (BMN 673) Monotherapy in Patients with Recurrent or Metastatic Solid Tumors Estudio de Fase 2, multicéntrico, abierto y exploratorio de biomarcadores, con talazoparib (BMN 673) en monoterapia, en pacientes con tumores sólidos recurrentes o metastásicos
The primary objective is to determine a potential association between HRD score and objective tumor response to talazoparib (BMN 673) treatment. El objetivo principal es determinar la posible as...
Country
None
organs
None
Specialty
None
Closed trial
More information
1
2
3
Next